Atkins MB - Search Results

1

Immunotherapy of metastatic renal cell carcinoma.

McDermott DF, Atkins MB. McDermott DF, et al. Among authors: atkins mb. Cancer J. 2008 Sep-Oct;14(5):320-4. doi: 10.1097/PPO.0b013e31818675c4. Cancer J. 2008. PMID: 18836337 Review.

2

Rapidly progressive glomerulonephritis after immunotherapy for cancer.

Parker MG, Atkins MB, Ucci AA, Levey AS. Parker MG, et al. Among authors: atkins mb. J Am Soc Nephrol. 1995 Apr;5(10):1740-4. doi: 10.1681/ASN.V5101740. J Am Soc Nephrol. 1995. PMID: 7787140 Review.

3

Mechanisms of action and toxicity of immunotherapy with cytokines.

Mier JW, Atkins MB. Mier JW, et al. Among authors: atkins mb. Curr Opin Oncol. 1993 Nov;5(6):1067-72. doi: 10.1097/00001622-199311000-00020. Curr Opin Oncol. 1993. PMID: 8305541 Review.

4

Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma.

Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB. Fallick ML, et al. Among authors: atkins mb. J Urol. 1997 Nov;158(5):1691-5. doi: 10.1016/s0022-5347(01)64097-7. J Urol. 1997. PMID: 9334580 Clinical Trial.

5

Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.

Dutcher JP, Atkins M, Fisher R, Weiss G, Margolin K, Aronson F, Sosman J, Lotze M, Gordon M, Logan T, Mier J. Dutcher JP, et al. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S73-8. Cancer J Sci Am. 1997. PMID: 9457399 Review.

6

A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.

McDermott DF, Trehu EG, Mier JW, Sorce D, Rand W, Ronayne L, Kappler K, Clancy M, Klempner M, Atkins MB. McDermott DF, et al. Among authors: atkins mb. Clin Cancer Res. 1998 May;4(5):1203-13. Clin Cancer Res. 1998. PMID: 9607578 Clinical Trial.

7

Immunotherapy and experimental approaches for metastatic melanoma.

Atkins MB. Atkins MB. Hematol Oncol Clin North Am. 1998 Aug;12(4):877-902, viii. doi: 10.1016/s0889-8588(05)70029-0. Hematol Oncol Clin North Am. 1998. PMID: 9759585 Review.

8

Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.

Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB. Gollob JA, et al. Among authors: atkins mb. Clin Cancer Res. 2000 May;6(5):1678-92. Clin Cancer Res. 2000. PMID: 10815886 Clinical Trial.

9

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.

McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB. McDermott DF, et al. Among authors: atkins mb. Clin Cancer Res. 2000 Jun;6(6):2201-8. Clin Cancer Res. 2000. PMID: 10873069 Clinical Trial.

10

Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12.

Gollob JA, Veenstra KG, Mier JW, Atkins MB. Gollob JA, et al. Among authors: atkins mb. J Immunother. 2001 Jan-Feb;24(1):91-8. doi: 10.1097/00002371-200101000-00011. J Immunother. 2001. PMID: 11211153 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

475 results

Search Page

Filters